Category - Developments

Developments

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

RenovoRX (NASDAQ:RNXT) has announced that an abstract presented at the ASCO Gastrointestinal Cancers Symposium 2025 highlights promising pharmacokinetic (PK) data from its patented Trans-Arterial Micro-Perfusion (TAMP)...

January 27, 2025

Developments

Veru reports positive topline results of Phase 2b study of enobosarm for weight loss

Veru (NASDAQ:VERU) has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction...

January 27, 2025

Developments

Social Capital’s Chamath Palihapitiya calls out Perimeter’s AI-driven cancer margin visualization technology on X show

Chamath Palihapitiya Renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, Chamath Palihapitiya, sat down with Tucker Carlson today to talk about several topics, including AI’s...

January 24, 2025

Developments

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

Greenwich LifeSciences (NASDAQ:GLSI) has announced the launch of two new clinical sites for its FLAMINGO-01 Phase 3 trial of GLSI-100 in HER2 breast cancer, including Harvard and Johns Hopkins Universities...

January 23, 2025

Developments

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that the European Medicines Agency (EMA) has granted a waiver allowing the company to bypass pediatric studies of mesdopetam, enabling a focus on patient groups...

January 23, 2025

Developments

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

IPA (ImmunoPrecise Antibodies) (NASDAQ:IPA) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and...

January 22, 2025

Developments

FDA grants RPDD to MeiraGTx’s treatment for LCA1

MeiraGTx (NASDAQ:MGTX) has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD)...

January 22, 2025

Developments

Revelation launches Phase 1b study of Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) has announced the commencement of its PRIME Phase 1b clinical study evaluating escalating doses of Gemini, its intravenously administrated proprietary formulation of phosphorylated...

January 21, 2025

Developments

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non...

January 21, 2025

Developments

BioNxt moves R&D to Gen-Plus in Munich

BioNxt Solutions (CSE:BNXT; OTC:BNXTF; FSE:BXT) has announced that it will transition its research and development activities to Gen-Plus, a contract research and development organization in Munich, Germany, effective...

January 21, 2025

Category - Developments

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

Veru reports positive topline results of Phase 2b study of enobosarm for weight loss

Social Capital’s Chamath Palihapitiya calls out Perimeter’s AI-driven cancer margin visualization technology on X show

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

FDA grants RPDD to MeiraGTx’s treatment for LCA1

Revelation launches Phase 1b study of Gemini in CKD

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

BioNxt moves R&D to Gen-Plus in Munich

General

More